Determination of fenticonazole enantiomers by LC-ESI-MS/MS and its application to pharmacokinetic studies in female rats

Abstract

A simple, rapid, and specific high-performance liquid Chromatograph coupled with a tandem mass spectrometry method has been developed and validated for the determination of fenticonazole (CAS 72479-26-6) enantiomers in rat plasma. Simple protein precipitation by acetonitrile was utilized for extracting analytes from the plasma samples. Chromatography separation was performed on a C₁₈ analytical column (150 mm × 2.0 mm, 5 µm) with a mobile phase consisting of methanol-10 mM aqueous ammonium acetate (adjusted to pH 3.5 with acetic acid) (90:10, v/v) at a flow rate of 0.2 ml/min. Detection was carried out on a triple quadrupole mass spectrometer equipped with electrospray ionization (ESI) source, and operated in multiple-reaction monitoring (MRM) mode. The calibration curves were linear over the range 0.5 – 200 ng/ml (r > 0.99). The relative recoveries of R-(−)-fenticonazole and its enantiomer were better than 85%. The intra- and inter-day precisions (R.S.D.%) and deviations of the assay accuracies were less than 10%. This newly developed and validated method was successfully applied to pharmacokinetic studies after administration at a single dose of 20 mg/kg R-(−)-fenticonazole nitrate and its enantiomer to female rats per vagina. The C_max value of S-(+)-fenticonazole was greater than that of R-(−)-fenticonazole by 1.36-fold, whereas, the t_1/2 ß and MRT values of R-(−)-fenticonazole were longer than those of its enantiomer by 1.95- and 1.24-fold. The results indicated that S-(+)-fenticonazole was faster in absorption and elimination in female rat. But, the T_max and AUC_(0–12) values for each of fenticonazole enantiomers were not significantly different.

Key words

Antifungal agent - Enantiomer - Fenticonazole - Pharmacokinetics - Liquid chromatography/tandem mass spectrometry (LC-MS/MS)

• References

• 1 Fromting RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988; 1 (2) 187-217
• 2 Veraldi S, Milani R. Topical fenticonazole in dermatology and gynaecology: current role in therapy. Drugs. 2008; 68 (15) 2183-94
• 3 Antonopoulou S, Aoun M, Alexopoulos EC, Baka S, Logothetis E, Kalambokas T et al. Fenticonazole activity measured by the methods of the European committee on antimicrobial susceptibility testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes. Antimicrob Agents Chemother. 2009; 53 (5) 2181-4
• 4 Qian MR, Zeng S. Pharmacokinetics of chiral drugs. Asian J Drug Metab Pharmacokinet. 2003; 3: 99-103
• 5 Hong YJ, Gao LB, Zeng S. Enantioselective analytical methods in chiral drug metabolism. J Chin Pharm Sci. 2008; 17: 177-82
• 6 Rentsch KM. The importance of stereoselective determination of drugs in the clinical laboratory. J Biochem Biophys Methods. 2002; 54: 1-9
• 7 Quaglia MG, Donati E, Desideri N, Fanali S, Dauria FD, Tecca M. Chiral discrimination by HPLC and CE and antifungal activity of racemic fenticonazole and its enantiomers. Chirality. 2002; 14: 449-454
• 8 Speed W, Long JM, Simmonds RJ, Enos TA. The development and validation of a high performance liquid chroma-tography(HPLC)/tandem mass spectrometry assay for fenticonazole in human plasma and comparison with an HPLC-UV method. Rapid Commun Mass Spectrom. 1995; 9: 1452-6
• 9 FDA, Guidance for Industry, Bioanalytical Method Validation, May 2001.